Clinical trials: Transcription Factors
Infections, Pneumonia
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
The Hyper IgE Syndromes (HIES) are primary immunodeficiencies resulting in eczema and recurrent skin and lung infections. Autosomal dominant Hyper IgE syndrome (AD-HIIES; Job's syndrome) is caused by STAT3 mutations, and is a…
- Conditions
- Infections, Pneumonia, Immune System Diseases, STAT3 Transcription Factor
- Trial name
- NCT00006150
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Melasma
Tissue-resident Memory T Cells Expression in Melasma
The treatment of melasma and the maintenance of depigmentation represent a challenge due to its frequent recurrences. Pathophysiological mechanisms and factors have been linked to melasma such as inflammation, sun exposure…
- Trial name
- NCT05698342
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Universidad Autonoma de San Luis Potosí
Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS)
Phase 2 Study in Patients With MiT Tumors
This is a multi-center, single arm intended to evaluate the anti-tumor effect of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors.
- Conditions
- Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS), Clear Cell Sarcoma (CCS)
- Trial name
- NCT00557609
- Testing
- ARQ 197
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 47 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor
Lurbinectedin in FET-Fused Tumors
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
- Conditions
- Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
- Trial name
- LiFFT (NCT05918640)
- Testing
- Lurbinectedin
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Children's Hospital of Philadelphia